CpG News and Research

RSS

Neutral or awkward behavior of mothers with infants linked to an epigenetic change in children

Adding evidence to the importance of early development, a new study links neutral maternal behavior toward infants with an epigenetic change in children related to stress response.

2 Mar 2023

Study may elucidate metformin's potential role in longevity through DNA methylation

A new research paper was published in Aging (listed as "Aging (Albany NY)" by MEDLINE/PubMed and "Aging-US" by Web of Science) Volume 15, Issue 3, entitled, "Metformin use history and genome-wide DNA methylation profile: potential molecular mechanism for aging and longevity."

22 Feb 2023

Novel COVID-19 protein component vaccine elicits durable immune response in rodents

Researchers describe a novel SARS-CoV-2 spike protein component vaccine called MT-001.

9 Feb 2023

A single base-resolution sequencing methodology that sequences the two most common cytosine modifications in a single workflow

Researchers developed a WGS method that read four canonical DNA bases, viz., adenine (A), cytosine (C), guanine (G), and thymine (T) plus 5mC and 5hmC, epigenetic variants of unmodified C to yield an accurate six-letter digital readout in a single workflow.

9 Feb 2023

Researchers identify potent pan-sarbecovirus antibodies from non-human primates vaccinated with an AS03 adjuvanted subunit SARS-CoV-2 vaccine

Researchers assessed the effectiveness of pan-sarbecovirus-neutralizing antibodies against SARS-CoV-2.

24 Jan 2023

Research explores the utility of epigenetically predicted BMI

DNA methylation is an accurate predictor of current BMI and a poor predictor of future BMI.

18 Jan 2023

The main source of editing of the mpox virus genome during the 2022 outbreak

Researchers investigated the main source of editing of the 2022 mpox virus genome.

11 Jan 2023

COVID-19 vaccine potency and breadth improved by nanoparticle-conjugated adjuvants

In a recent study posted to bioRxiv*, researchers designed a nanoparticle (NP)-conjugated toll-like receptor 9 (TLR9) agonist to improve the adjuvanticity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.

8 Jan 2023

Researchers report the development of robust candidate single immunization PNP hydrogel COVID vaccines

Researchers developed a one-dose subunit vaccine for the induction of durable, potent, and broad immunity against SARS-CoV-2.

16 Dec 2022

Colorectal cancer doesn’t wait - DNA methylation tests facilitate earlier treatment

In this interview, Yantao Li and Zhe Wang, Director of Cancer Early Screening Products and the Product Director of Oncology at BGI Genomics, talks to NewsMedical about colorectal cancer (CRC), including why incidences are important and the importance of screening.

From BGI Genomics 6 Dec 2022

NUS scientists develop novel low-cost method of testing for cancers

Scientists from the National University of have discovered a novel low-cost method of testing for cancers.

5 Dec 2022

Phase 2/3 clinical trial shows that Clover’s vaccine candidate reduces household transmission of SARS-CoV-2

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, and the International Vaccine Institute, an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, today announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

30 Nov 2022

Evaluating cell-free DNA-based blood tests for early detection of multiple cancers

Researchers assessed several approaches for a circulating cell-free deoxyribonucleic acid (cfDNA)-based multi-cancer early detection (MCED) test. Defining the clinical limit of detection (LOD) based on circulating tumor allele fraction (cTAF) enables the comparison of different approaches.

21 Nov 2022

Development of a potent, broadly protective vaccine against all SARS-CoV-2 variants

In a recent study published in the journal npj Vaccines, researchers in China designed, produced, and evaluated the neutralization efficacy of a recombinant coronavirus disease 2019 (COVID-19) vaccine containing four hot-spot substitution mutations based on a prefusion-stabilized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) trimer.

15 Nov 2022

The epigenetic alterations of monocytes in severe COVID-19

Researchers performed DNA methylation analysis on monocytes in the peripheral blood samples obtained from severe COVID-19 patients.

28 Oct 2022

Three-dose regimen of HEPLISAV-B vaccine fully protects people living with HIV, data shows

The AIDS Clinical Trials Group (ACTG), the world's largest HIV research network whose focus has expanded to include evaluating outpatient treatment for COVID-19, today presented a session demonstrating that a three-dose regimen of the HEPLISAV-B vaccine fully protected people living with HIV at IDWeek 2022, taking place in Washington D.C. from October 19-22, 2022.

20 Oct 2022

Three-dose course of the hepatitis B vaccine fully protects adults living with HIV

A three-dose course of the hepatitis B vaccine HEPLISAV-B fully protected adults living with HIV who had never been vaccinated against or infected with the hepatitis B virus (HBV), according to study findings presented today at the IDWeek conference in Washington, D.C.

20 Oct 2022

Pluripotent bat stem cells as a model to study novel viruses

Researchers generate induced pluripotent stem cells from bats using to establish bats as a novel in vivo model study species.

29 Sep 2022

Study finds telomeres can set damage thresholds for cancer cells above which they cannot continue to divide

A recent study hypothesized that ALT might compromise telomere integrity if not restricted appropriately.

21 Sep 2022

Molecular engineered low-cost highly effective RBD-based COVID vaccine

In a recent study posted to the bioRxiv* preprint server, an international team of researchers developed a second-generation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen (RBD-J6) by molecular engineering with two additional amino acid (aa) substitutions (S383D and L518D mutations) in a hydrophobic cryptic RBD core epitope to enhance stability and expression against SARS-CoV-2 variants of concern (VOCs).

19 Sep 2022